Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity

Phase 4

• Conditions: Overactive Detrusor
• Interventions: Drug: Botulinum toxin injected to bladder body; Drug: Botulinum toxin injected into trigone

• Registration Number: NCT02009540
• Lead Sponsor: Mr HD Flood

Brief Summary

Overactive Bladder (OAB) is a chronic condition caused by instability of the detrusor or bladder muscle, which gives rise to symptoms of urinary urgency and often urinary incontinence. Idiopathic Detrusor Overactivity (IDO) is a subset of OAB where the cause for the bladder muscle instability is unknown.

OAB is usually treated by conservative measures or with oral medications eg. anticholinergics. Injection of onabotulinum toxin A (onaBoNT-A) into the bladder wall is licenced in the treatment of refractory IDO where oral medications fail. The injected toxin paralyses the bladder by blocking the ability of certain (motor) nerves to communicate with the bladder muscle. As these nerves are mainly concentrated in what is known as the "body" of the bladder this is traditionally where the injections are given.

In addition to its action on motor nerves, onaBoNT-A also affects sensory nerve pathways. Recent studies show that IDO is caused by both motor and sensory nerve dysfunction, therefore injecting the "trigone", a part of the bladder where sensory nerves are particularly dense, may be of clinical benefit. Three studies comparing trigone versus trigone-sparing injection of botulinum toxin in the treatment of IDO have been carried out. One of these indicated a significant benefit in targeting the trigone and the other two did not show any difference.

Our study aims to examine if injection of onaBoNT-A into the trigone alone will provide symptom and functional improvement in patients with IDO by comparing peritrigonal injection of onaBoNT-A with the traditional method of injection which spares the trigone.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-11-29
• Status Verified: 2013-12
• Study Start: 2013-12
• Study First Submitted QC: 2013-12-08
• Last Update Submitted: 2013-12-08
• Study First Posted: 2013-12-12
• Last Update Posted: 2013-12-12
• Primary Completion: 2014-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Fulfil ICS criteria for OAB
• Urodynamically proven detrusor instability
• Symptoms lasting >6/12
• Patients must discontinue anticholinergic medication >14 days prior to randomisation and withhold the use of anticholinergics for the duration of the study.
• Patients with mixed incontinence are eligible if their urge symptoms are predominant. These will be instruced to record only episodes of urge urinary incontinence.
• Providing informed consent to participate in the study
• At least 18 years of age

Exclusion Criteria

• Previous BoNT-A injection within 9 months of randomisation
• History of any neurological condition e.g. MS, Parkinsons, CVA
• Contraindication to BoNT e.g. Myaesthenia gravis
• Urinary tract infection in previous 6/12
• Antimicrobial therapy in previous 6/12
• Previous or current diagnosis of prostate or bladder cancer
• History of treatment with cyclophosphamide
• Radiation cystitis
• Urethral dilatation, cystometrogram, bladder cystoscopy under anaesthetic or a bladder biopsy in previous 3/12
• Augmentation cystoplasty, cystectomy or neurectomy
• Urethral stricture of <12ch
• Pregnancy
• Sexually active women of childbearing potential who are unwilling to use contraceptive measures for the duration of the trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Botulinum toxin injected to bladder body	Botulinum toxin injected to bladder body	arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor.
Botulinum toxin injected into trigone	Botulinum toxin injected into trigone	Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml).

Primary Outcome Measures

Name	Time	Method
Global Response Assessment	measured at 3 months following intervention

Secondary Outcome Measures

Name	Time	Method
IIQ-7 quality of life questionnaire	measured at 3 months following intervention
Treatment tolerability - numerical rating scale (0-10)	measured at 2 weeks following intervention
UDI-6 quality of life questionnaire	measured at 3 months following intervention
Functional outcomes - 3 day sensation related bladder diary	measured at 3 months following intervention	Three day sensation related bladder diary

Trial Locations

Locations (1)

University Hospital of Limerick; 🇮🇪 Limerick, Ireland